Rituximab After Stem Cell Transplant Boosts Survival in Mantle Cell Lymphoma – Cancer Therapy Advisor
|
Rituximab After Stem Cell Transplant Boosts Survival in Mantle Cell Lymphoma
Cancer Therapy Advisor Maintenance rituximab (MR) after autologous stem cell transplant (ASCT) confers a benefit in progression-free survival in patients with mantle cell lymphoma (MCL), but additional studies are required in order to confirm that it confers an overall … |
